Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,337 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Evaluating Clear all
Completed Phase 3 Interventional Results available

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

NCT00679432
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Blood sampling, endoscopy, budesonide-MMX® 6 mg, budesonide-MMX® 9 mg, Placebo, Asacol® 400 mg
Procedure · Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
76
States / cities
Huntsville, Alabama • Mobile, Alabama • Sylacauga, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 4, 2026, 4:04 AM EDT
Terminated Phase 2 Interventional Results available

Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract

NCT04633187
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
16 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 4, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NCT06131398
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
AMG 355, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Duarte, California • Merriam, Kansas • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 4, 2026, 4:04 AM EDT
Recruiting Phase 1 Interventional

Evaluating the Pharmacokinetics and Safety of Miricorilant

NCT07553663
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
Miricorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 4, 2026, 4:04 AM EDT
Terminated Phase 1Phase 2 Interventional

A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma

NCT00733798
View directory record Official record
Conditions
Melanoma, Malignant Melanoma, Metastatic Melanoma
Interventions
131I-TM601
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Grand Rapids, Michigan • New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2009 · Synced Sep 4, 2026, 4:04 AM EDT
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Placebo, CDK4/6i, Letrozole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
61
States / cities
Goodyear, Arizona • Phoenix, Arizona • Burbank, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 4, 2026, 4:04 AM EDT
Completed Phase 2Phase 3 Interventional

A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders

NCT01550484
View directory record Official record
Conditions
Parkinson's Disease, Primary Parkinsonism, Lewy Body Parkinson's Disease
Interventions
18F-AV-133
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
14
States / cities
Scottsdale, Arizona • Sun City, Arizona • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 4, 2026, 4:04 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating Georgia Part C Implementation Outcomes

NCT07148258
View directory record Official record
Conditions
Communication Disorder, Childhood, Autism
Interventions
Project ImPACT Training As Usual, Project ImPACT Training Plus Co-Production, Routine Project ImPACT
Other · Behavioral
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 4, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

NCT00451958
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix 80 mg / Degarelix 80 mg, Degarelix 160 mg / Degarelix 160 mg, Leuprolide 7.5 mg / Degarelix 80 mg, Leuprolide 7.5 mg / Degarelix 160 mg
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
Homewood, Alabama • Laguna Hills, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 4, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)

NCT02626026
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tirabrutinib, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
9
States / cities
Sacramento, California • Miami, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 4, 2026, 4:04 AM EDT
Completed Not applicable Interventional Results available

Evaluating Anatomic Versus Targeted Lead Placement for Burst Stimulation Therapy During the Trial

NCT03277378
View directory record Official record
Conditions
Chronic, Intractable Pain of the Trunk and/or Lower Limbs
Interventions
lead placement followed by BurstDR stimulation
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
Santa Rosa, California • Clearwater, Florida • Merritt Island, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 4, 2026, 4:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Intercostobrachial Nerve Block's Effect on Pain Control After Shoulder Replacement

NCT06042608
View directory record Official record
Conditions
Postoperative Pain, Acute, Shoulder Pain
Interventions
intercostobrachial nerve block
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 4, 2026, 4:04 AM EDT
Completed Not applicable Interventional Results available

An Open Single-centre Investigation Evaluating Efficacy in Second Degree Partial Thickness Burns Using a Silicone Contact Layer Containing Silver.

NCT01734317
View directory record Official record
Conditions
Wound Healing
Interventions
Mepilex Transfer Ag
Device
Lead sponsor
Molnlycke Health Care AB
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Tampa, Florida • Garden City, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 4, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis

NCT06039189
View directory record Official record
Conditions
Moderate Plaque Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
45
States / cities
Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 4, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis

NCT00601484
View directory record Official record
Conditions
Cystitis, Interstitial
Interventions
PF-04383119, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
34
States / cities
Peoria, Arizona • Fresno, California • Glendora, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 4, 2026, 4:04 AM EDT
Completed Phase 2Phase 3 Interventional

Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS

NCT02231008
View directory record Official record
Conditions
Smith-Magenis Syndrome, Circadian
Interventions
tasimelteon, placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
3 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
4
States / cities
Santa Monica, California • Baltimore, Maryland • Chevy Chase, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Sep 4, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating the Effects of Avanafil on Semen Parameters

NCT01768676
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
avanafil, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
15
States / cities
Huntsville, Alabama • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 4, 2026, 4:04 AM EDT
Terminated Phase 3 Interventional Results available

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

NCT04161885
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Cancer
Interventions
Venetoclax, Azacitidine, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
43
States / cities
Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 4, 2026, 4:04 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Autologous Bone Marrow Aspirate (IV) and Bone Marrow Concentrate (Intranasal) for Parkinson's Disease and Parkinson-Plus Syndromes (SPARC-PD)

NCT07751640
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Interventions
Autologous Bone Marrow Aspirate (BMA) and Bone Marrow Aspirate Concentrate (BMAC)
Biological
Lead sponsor
Apeiron Research Center
Other
Eligibility
40 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 4, 2026, 4:04 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Implementation and Effectiveness of the BJC-Pink and Pearl Project on Lung Cancer Screening

NCT06898333
View directory record Official record
Conditions
Lung Cancer, Cancer of the Lung
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Creve Coeur, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 4, 2026, 4:04 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Immune Defense Protein Impact On Respiratory Immune Outcomes

NCT07431840
View directory record Official record
Conditions
Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
Interventions
Immune Defense Protein 50mg Dose, IDP 200mg Dose, Matching Placebo
Dietary Supplement
Lead sponsor
Quantec Ltd
Industry
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 4, 2026, 4:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.

NCT03379168
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Microfragmented Adipose Tissue (Lipogems), Corticosteroid injection, Saline
Device · Drug
Lead sponsor
Dustin L. Richter, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 4, 2026, 4:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic

NCT04459455
View directory record Official record
Conditions
Anxiety
Interventions
Contain COVID Anxiety SSI, Remain COVID Free SSI
Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 4, 2026, 4:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Single-Session Intervention Targeting Self-Injurious Behavior in Adolescents

NCT04498143
View directory record Official record
Conditions
Nonsuicidal Self Injury, Self Hatred, Suicidal Thoughts, Suicide Attempts
Interventions
Project SAVE ("Stop Adolescent Violence Everywhere") SSI, Active Comparator: Supportive Therapy ("Share Your Feelings") SSI
Other
Lead sponsor
University of Denver
Other
Eligibility
13 Years to 16 Years
Enrollment
565 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 4, 2026, 4:04 AM EDT